بدائل البحث:
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), mean decrease (توسيع البحث), gy decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
greater decrease » greatest decrease (توسيع البحث), greater increase (توسيع البحث), greater disease (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), mean decrease (توسيع البحث), gy decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
-
7041
Comparison of demographic features.
منشور في 2025"…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…"
-
7042
Data.
منشور في 2025"…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…"
-
7043
Comparison of examination test and treatment.
منشور في 2025"…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…"
-
7044
Specifications of prototypes of RSSCA system.
منشور في 2025"…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …"
-
7045
Software testing process flowchart.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7046
The ROC of LR for three classes.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7047
The ROC of MNB for three classes.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7048
Problem solution process model.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7049
The ROC of SVM for three classes.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7050
The ROC of RF for three classes.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7051
The ROC of GNB for three classes.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7052
The accuracy of classifiers and voting plans.
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7053
Metrics formula [24].
منشور في 2025"…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…"
-
7054
-
7055
Baseline characteristics of participants.
منشور في 2025"…In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m<sup>2</sup> was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34–0.36]). …"
-
7056
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7057
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7058
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
7059
Supplementary file 1_Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III tria...
منشور في 2025"…</p>Conclusion<p>Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. …"
-
7060